Skip to main content

Table 3 Prognostic value of chemotherapy-associated lymphopenia <0.91 × 10 9 /L for OS of colorectal cancer

From: The impact of chemotherapy-associated neutrophil/ lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer

Variables

Hazard ratio

95% confidence intervals

P-value

Pretreatment albumin

   

≥35 g/L

1.00(ref.)

  

<35 g/L

1.140

0.648-2.007

0.649

Pretreatment CEA a

   

<10 ng ml-1

1.00(ref.)

  

≥10 ng ml-1

1. 900

1.056-3.416

0.032

Differentiation

   

Well

1.00(ref.)

  

Moderately

0. 865

0. 323–2.314

0.772

Low

1.097

0.311-3.871

0.885

Sex

   

Male

1.00(ref.)

  

Female

0.856

0.493-1.489

0.583

Age

   

≤49 years

1.00(ref.)

  

50-60 yeas

1.514

0.625-3.666

0.359

>60 years

1.587

0.698-3.607

0.271

Location

   

Rectum

1.00(ref.)

  

Left colon cancer

1.067

0.564-2.019

0.843

Right colon cancer

0.647

0.296-1.414

0.275

Stage

   

II

1.00(ref.)

  

III

3.641

1.980-6.697

<0.0001

Duration of lymphopenia <1.0 × 10 9 L

   

≤28 days

1.00(ref.)

  

> 28 days

0.770

0.341-1.740

0.530

Chemotherapy-associated lymphocyte counts

   

Lymphocyte counts ≥ 0.66 × 109/L

1.00(ref.)

  

Lymphopenia <0.66 × 109/L

2.083

1.103-3.936

0.024

  1. a Carcinoembryonic antigen.